Researcher
Max Mazzone
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Mazzone Max (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Mazzone Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Tumor Inflammation and Angiogenesis (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → 30 Sep 2022
Projects
1 - 10 of 63
- Targeting the DNA methylation profile of cytotoxic T cells to overcome immunotherapy resistance of pancreatic cancerFrom5 Mar 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding glutamate metabolism in the tumor microenvironment to tackle Immune Checkpoint Blockade (ICB) resistanceFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Role of SLC1A3 in tumor-associated macrophages during immunotherapy resistance onset in breast cancerFrom1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Targeting the CDA/P2Y6 axis to overcome immunosuppression and favor response to immune checkpoint inhibitors in pancreatic cancerFrom1 Jul 2023 → TodayFunding: Other federal public and semi-governmental institutions
- Tackling tumor immunosuppression by reprograming eicosanoid metabolism and signaling in the tumor microenvironmentFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Understanding the roles of the epigenetic machinery in shaping distinct tumor-associated macrophage phenotypes.From10 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tackling SLC1A3 in tumor-associated macrophages to overcome anti-PD1 immunotherapy resistance in breast cancerFrom31 Oct 2022 → TodayFunding: FWO Strategic Basic Research Grant
- LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- BD Imaging Cell Sorter – BD Cell View TechnologyTMFrom24 Jun 2022 → TodayFunding: Other federal scientific institutions
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
1 - 10 of 179
- A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in Cancer(2023)
Authors: Ria Pinioti, Susan Schlenner, Bernard Thienpont, Abhishek Garg, Max Mazzone
Pages: 1611 - 1629 - Candida albicans stimulates formation of a multi-receptor complex that mediates epithelial cell invasion during oropharyngeal infection(2023)
Authors: Max Mazzone
- A metabolic gene survey pinpoints fucosylation as a key pathway underlying the suppressive function of Regulatory T cells in cancer.(2023)
Authors: Ria Pinioti, Max Mazzone, Mario di Matteo
Number of pages: 19 - Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding(2023)
Authors: Maxim De Schepper, Tatjana Geukens, Stefaan Soenen, Christine Desmedt, Colinda Scheele, Anna Sablina, Max Mazzone
- A collaborative synthetase(2023)
Authors: Max Mazzone
Pages: 255 - 256 - PHD2 Constrains Antitumor CD8+T-cell Activity(2023)
Authors: Max Mazzone
Pages: 339 - 350 - A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling(2023)
Authors: Ginevra Doglioni, Alex Cuadros, Xiaozheng Liu, dorien Broekaert, Sofie Demeyer, Xander Spotbeen, Margherita Demicco, François Richard, Tatjana Geukens, Maxim De Schepper, et al.
Pages: 344 - + - Mitochondria metabolism sets the species-specific tempo of neuronal development(2023)
Authors: Ryohei Iwata, Pierre Casimir, Emir Erkol, Sofie Beckers, Anke Vandekeere, Pieter Vermeersch, Sebastien Carpentier, Kristofer Davie, Max Mazzone, Stein Aerts, et al.
Pages: 553 - + - Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer(2023)
Authors: Federica Cappellesso, Max Mazzone, Baki Topal
Number of pages: 37 - Stroma-derived miR-214 coordinates tumor dissemination.(2023)
Authors: Max Mazzone
Pages: 20
Patents
1 - 10 of 10
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)
- Biomarker for anti-tumor therapy (Inventor)
- Combination of p2y6 inhibitors and immune checkpoint inhibitors (Inventor)
- Inhibition of slc4a4 in the treatment of cancer (Inventor)
- Means and methods to treat inflammatory diseases (Inventor)
- Glutamine dehydrogenase inhibitors for use in muscle regeneration (Inventor)
- Cd8+ t-cells lacking plexins and their application in cancer treatment (Inventor)
- Podoplanin positive macrophages (Inventor)
- Cancer treatment by targeting plexins in the immune compartment (Inventor)